KR100986194B1 - 인지능 유지 향상을 위한 스타틴 요법 - Google Patents

인지능 유지 향상을 위한 스타틴 요법 Download PDF

Info

Publication number
KR100986194B1
KR100986194B1 KR1020047013127A KR20047013127A KR100986194B1 KR 100986194 B1 KR100986194 B1 KR 100986194B1 KR 1020047013127 A KR1020047013127 A KR 1020047013127A KR 20047013127 A KR20047013127 A KR 20047013127A KR 100986194 B1 KR100986194 B1 KR 100986194B1
Authority
KR
South Korea
Prior art keywords
galantamine
statin
dementia
statins
active ingredient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020047013127A
Other languages
English (en)
Korean (ko)
Other versions
KR20040096608A (ko
Inventor
시안 릴리엔펠드
엘렌엠. 구테르만
로이스톤존 글래스풀
Original Assignee
얀센 파마슈티카 엔.브이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 얀센 파마슈티카 엔.브이. filed Critical 얀센 파마슈티카 엔.브이.
Publication of KR20040096608A publication Critical patent/KR20040096608A/ko
Application granted granted Critical
Publication of KR100986194B1 publication Critical patent/KR100986194B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)
  • Indole Compounds (AREA)
KR1020047013127A 2002-04-02 2003-03-28 인지능 유지 향상을 위한 스타틴 요법 Expired - Fee Related KR100986194B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36928502P 2002-04-02 2002-04-02
US60/369,285 2002-04-02
PCT/EP2003/003324 WO2003082298A1 (en) 2002-04-02 2003-03-28 Statin therapy for enhancing cognitive maintenance

Publications (2)

Publication Number Publication Date
KR20040096608A KR20040096608A (ko) 2004-11-16
KR100986194B1 true KR100986194B1 (ko) 2010-10-07

Family

ID=28675573

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020047013127A Expired - Fee Related KR100986194B1 (ko) 2002-04-02 2003-03-28 인지능 유지 향상을 위한 스타틴 요법

Country Status (21)

Country Link
EP (1) EP1492539B1 (https=)
JP (1) JP2005525391A (https=)
KR (1) KR100986194B1 (https=)
CN (1) CN100528164C (https=)
AT (1) ATE331523T1 (https=)
AU (1) AU2003226753B2 (https=)
BR (1) BR0308293A (https=)
CA (1) CA2480275C (https=)
CY (1) CY1105545T1 (https=)
DE (1) DE60306503T2 (https=)
DK (1) DK1492539T3 (https=)
EA (1) EA013069B1 (https=)
ES (1) ES2268393T3 (https=)
IL (2) IL164317A0 (https=)
MX (1) MXPA04009535A (https=)
NO (1) NO20044698L (https=)
NZ (1) NZ536111A (https=)
PL (1) PL211160B1 (https=)
PT (1) PT1492539E (https=)
UA (1) UA79605C2 (https=)
WO (1) WO2003082298A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004071431A2 (en) * 2003-02-05 2004-08-26 Myriad Genetics, Inc. Method and composition for treating neurodegenerative disorders
MXPA06011969A (es) * 2004-04-14 2006-12-15 Warner Lambert Co Combinacion terapeutica para tratamiento de la enfermedad de alzheimer.
WO2005123068A2 (en) * 2004-06-08 2005-12-29 Axonyx, Inc. Methods of dealying alzheimer’s disease progression using a beta-amyloid precursor protein inhibitor and a hmg coa reductase inhibitor
GB0607946D0 (en) * 2006-04-21 2006-05-31 Minster Res The Ltd Mono and combination therapy
AU2007299726A1 (en) * 2006-09-22 2008-03-27 Braincells, Inc. Combination comprising an HMG-COA reductase inhibitor and a second neurogenic agent for treating a nervous system disorder and increasing neurogenesis
TWI432195B (zh) 2007-10-03 2014-04-01 Kowa Co 神經細胞死亡抑制劑
WO2015089349A1 (en) * 2013-12-13 2015-06-18 Tabaczynski David A Inhibition of isoprenoid biosynthetic pathways to treat neuroinflammatory disorders

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW506836B (en) * 1996-06-14 2002-10-21 Janssen Pharmaceutica Nv Fast-dissolving galanthamine hydrobromide tablet

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
International Journal of Geriatric Psychopharmacology, 1(4), pp. 197-201 (1998)
The Lancet, 356(9242), pp. 1627-1637 (2000)

Also Published As

Publication number Publication date
NO20044698L (no) 2004-10-29
IL164317A (en) 2010-04-29
EA013069B1 (ru) 2010-02-26
PL371551A1 (en) 2005-06-27
EP1492539A1 (en) 2005-01-05
AU2003226753A1 (en) 2003-10-13
CN100528164C (zh) 2009-08-19
AU2003226753B2 (en) 2007-06-28
IL164317A0 (en) 2005-12-18
JP2005525391A (ja) 2005-08-25
CA2480275A1 (en) 2003-10-09
EA200401295A1 (ru) 2005-02-24
WO2003082298A1 (en) 2003-10-09
CA2480275C (en) 2011-08-16
NZ536111A (en) 2006-03-31
EP1492539B1 (en) 2006-06-28
CN1642555A (zh) 2005-07-20
DE60306503D1 (de) 2006-08-10
CY1105545T1 (el) 2010-07-28
BR0308293A (pt) 2004-12-28
UA79605C2 (en) 2007-07-10
KR20040096608A (ko) 2004-11-16
PL211160B1 (pl) 2012-04-30
PT1492539E (pt) 2006-11-30
DE60306503T2 (de) 2007-06-21
DK1492539T3 (da) 2006-10-30
ES2268393T3 (es) 2007-03-16
ATE331523T1 (de) 2006-07-15
MXPA04009535A (es) 2005-01-25
HK1079688A1 (zh) 2006-04-13

Similar Documents

Publication Publication Date Title
EP1001760B1 (en) Composition for controlling mood disorders in healthy individuals
DE60009697T2 (de) Verwendung von 1-[4-(5-cyanoindol-3yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazin und dessen physiologisch akzeptablen salzen zur behandlung von bipolaren krankheiten und manie
EP1423127A1 (en) Treatment of dementia and memory disorders with anticonvulsants and acetylcholinesterase inhibitors
US20130150434A1 (en) Methods of using low-dose doxepin for the improvement of sleep
US6835728B2 (en) Drug combination for the treatment of depression and related disorders comprising mirtazapine
KR100986194B1 (ko) 인지능 유지 향상을 위한 스타틴 요법
CN114259486A (zh) 木犀草素及其药物组合物的应用
US20050222122A1 (en) Statin therapy for enhancing cognitive maintenance
Chakravarti et al. Zuclopenthixol acetate (5% in ‘Viscoleo’): single-dose treatment for acutely disturbed psychotic patients
US20250288591A1 (en) Trimeprazine for use in treating trigeminal neuralgia and for reducing pain related thereto
HK1079688B (en) Statin product for enhancing cognitive maintenance
JP4011669B2 (ja) 脊髄損傷に対する治療剤
CN116270582A (zh) 非诺贝特的用途
AU2002323467A1 (en) Treatment of dementia and memory disorders with anticonvulsants and acetylcholinesterase inhibitors
CZ20022320A3 (cs) Kombinace účinných látek a její použití pro výrobu farmaceutického prostředku

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20130924

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 20140923

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

FPAY Annual fee payment

Payment date: 20150918

Year of fee payment: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

FPAY Annual fee payment

Payment date: 20160920

Year of fee payment: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

FPAY Annual fee payment

Payment date: 20170919

Year of fee payment: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

FPAY Annual fee payment

Payment date: 20180903

Year of fee payment: 9

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 9

FPAY Annual fee payment

Payment date: 20190917

Year of fee payment: 10

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 10

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 11

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20211002

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20211002

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000